Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 16 to 30 of 227 results for headache

  1. Topiramate to prevent recurrent cluster headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache?

    prevent recurrent cluster headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster...

    Research recommendation
    Published
    9 June 2015

  2. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA659

  3. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Rimegepant for preventing migraine (TA906)

    Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA906

  5. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

    Evidence summary
    Published
    30 September 2014

  6. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

    Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    26 March 2013

  7. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA764

  8. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA919

  9. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    10 March 2021
    View recommendations

    Sections for TA682

  10. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    22 January 2013

  11. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.

    Highly specialised technologies guidance
    Published
    28 January 2015
    View recommendations

    Sections for HST1

  12. NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether the procedure is used for treatment or prevention, and whether it is used for cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device  durability. NICE may update this guidance on publication of further evidence.

    transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether...

    Research recommendation
    Published
    6 April 2016

  13. NICE encourages further research on sphenopalatine ganglion stimulation for chronic cluster headache. Reported outcomes should include long-term efficacy and device durability.

    further research on sphenopalatine ganglion stimulation for chronic cluster headache. Reported outcomes should include long-term...

    Research recommendation
    Published
    6 October 2015

  14. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)

    Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).

    Technology appraisal guidance
    Published
    23 January 2001
    View recommendations

    Sections for TA20

  15. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

    Highly specialised technologies guidance
    Published
    22 February 2017
    View recommendations

    Sections for HST4